Global Nucleic Acid Therapeutics Market - 2025 - 2033

Global Nucleic Acid Therapeutics Market - 2025 - 2033

The global nucleic acid therapeutics market reached US$ 5.64 billion in 2024 and is expected to reach US$ 14.42 billion by 2032, growing at a CAGR of 10.9% during the forecast period 2025-2032.

Nucleic acid therapeutics are a class of treatments that involve the use of nucleic acids, such as DNA, RNA, or modified forms of these molecules, to treat or prevent diseases. These therapies work by targeting the genetic material within cells to either correct genetic mutations, modulate gene expression, or inhibit the activity of disease-causing proteins.

Nucleic acid-based treatments can include a wide range of approaches, such as gene therapy, RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies, each designed to address different types of diseases, particularly those with genetic origins like cancer, neurological disorders, and rare inherited conditions.

Market Dynamics: Drivers & Restraints

Growing Investments in Research and Development

Increasing investments in research and development (R&D) are expected to play a crucial role in driving the growth of the nucleic acid therapeutics market. As funding for R&D rises, pharmaceutical companies are expanding their portfolios with innovative nucleic acid-based treatments, advancing them from clinical trials to real-world use. For instance, in March 2022, RNAimmune, Inc. secured an approximately US$27 million Series A round of financing. The Company intends to use the funding to accelerate its research and development of mRNA vaccine and drug discovery focused on infectious diseases, cancer, and rare diseases.

These investments are encouraging collaboration between academic institutions, research organizations, and biotech firms, creating a strong network that fosters the development of breakthrough therapies. For instance, in August 2024, Novartis and Versant Ventures unveiled Borealis Biosciences with $150 million in combined Series financing and strategic research collaboration funding to target next-generation RNA medicines for kidney diseases.

Additionally, R&D efforts are addressing critical challenges in delivery methods, stability, and targeting, which are essential for improving the effectiveness of nucleic acid therapeutics. With a greater emphasis on R&D, the market is witnessing the emergence of transformative therapies that have the potential to revolutionize treatment options and significantly improve patient outcomes.

Challenges in delivering nucleic acid therapeutics

Challenges in delivering nucleic acid therapeutics significantly restrain the market due to the inherent complexities associated with effectively targeting and entering cells. Nucleic acids, such as RNA and DNA, are large and negatively charged molecules that are vulnerable to degradation by nucleases in bodily fluids, which complicates their stability and bioavailability. Additionally, achieving efficient cellular uptake is a major hurdle; many delivery systems, including viral and non-viral vectors, struggle with low transfection efficiencies in vivo.

Segment Analysis

The global Nucleic Acid Therapeutics market is segmented based on category, application, end-user, and region.

Category:

Antisense Oligonucleotides (ASOs) segment is expected to dominate the global Nucleic Acid Therapeutics share

Antisense oligonucleotides (ASOs) are expected to dominate the nucleic acid therapeutics market due to their unique ability to target and regulate specific genes involved in a variety of diseases, including genetic disorders, cancer, and viral infections. ASOs work by binding to messenger RNA (mRNA) and modifying gene expression, effectively silencing harmful genes or correcting genetic mutations at the molecular level. This precision in targeting makes ASOs a powerful tool for personalized medicine, particularly for conditions that have limited treatment options.

The growing success of ASOs in clinical trials, along with their approval for treating diseases like spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD), is driving their widespread adoption. Additionally, advancements in delivery technologies are improving the effectiveness and safety of ASOs, further boosting their market potential. As more ASO-based therapies receive regulatory approval and new applications are explored, the demand for ASOs is expected to continue rising.

Geographical Analysis

North America is expected to hold a significant position in the global Nucleic Acid Therapeutics share

North America is expected to hold a significant portion of the nucleic acid therapeutics market share. This is due to the high level of investment in biotechnology and pharmaceutical research, and the presence of leading biopharmaceutical companies that are actively developing and commercializing nucleic acid-based therapies.

The presence of a large number of market players is encouraging the players to invest and develop new therapeutics. Several players are investing in the research and development of advanced therapeutics in the region. For instance, in October 2024, Leal Therapeutics, Inc. announced a $45 million financing. The round was led by Newpath Partners, with additional new investors Chugai Venture Fund and Alexandria Venture Investments, in addition to existing investors OrbiMed, Euclidean Capital and PhiFund. This latest financing round follows a previously disclosed $39 million financing.

The increasing prevalence of genetic disorders, cancer, and infectious diseases in North America is expected to create a strong demand for innovative and personalized treatment options, including nucleic acid therapeutics.

Asia Pacific is at the fastest-growing pace in the global Nucleic Acid Therapeutics market share

The Asia-Pacific region is experiencing the fastest growth in the global nucleic acid therapeutics market, driven by several key factors. Rapid advancements in biotechnology and an increasing focus on innovative medical treatments are positioning the region as a hub for cutting-edge research and development.

The growing prevalence of genetic disorders, cancer, and infectious diseases, coupled with a rising demand for personalized medicine, is fuelling the adoption of nucleic acid-based therapies. Additionally, significant investments in healthcare infrastructure, particularly in countries like China, Japan, and India, are enabling greater access to advanced therapeutics.

Competitive Landscape

The major global players in the market include Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Inc., Gilead Sciences, Inc., AstraZeneca, Sarepta Therapeutics, Inc., Creative Biolabs, GSK plc, Novartis AG, BioNTech SE., and Silence Therapeutics among others.

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Nucleic Acid Therapeutics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.